PureTech Health stock analysis
PureTech Health (0VQ0) Stock Price & Analysis
0VQ0 Stock Chart & Stats
- Day’s Range
- EUR 13.80 - EUR 14.00
- 52-Week Range
- EUR 11.30 - EUR 16.90
- Previous Close
- EUR 13.50
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 359.10M
- Enterprise Value
- EUR 243.44M
- Total Cash (Recent Filing)
- EUR 278.89M
- Total Debt (Recent Filing)
- EUR 19.76M
- Price to Earnings (P/E)
- 167.3
- Beta
- 0.73
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Capital-efficient Portfolio Model
The hub-and-spoke structure can fund later-stage development outside PureTech while preserving meaningful economic interests. This supports capital efficiency, reduces reliance on parent-level dilution, and creates multiple routes to value realization through equity, royalties, milestones and monetization.
Extended Cash Runway And Lower Burn
A runway extending through 2028 gives management time to advance programs and pursue monetization without immediate financing pressure. The lower expected burn rate should preserve flexibility, although the benefit depends on executing planned development and investment decisions.
Clinical And Regulatory Portfolio Progress
Progress across multiple founded entities demonstrates that PureTech is converting its platform into externally financed clinical and commercial assets. IPO execution, late-stage development and regulatory support can broaden future royalty, milestone and equity-value opportunities.
Bears Say
Persistent Operating Losses
Limited and volatile revenue alongside recurring operating losses indicates that the business has not yet established dependable earnings from its portfolio. Continued development spending may therefore remain necessary before the platform can produce consistently self-funded profitability.
Sustained Negative Cash Generation
Persistent negative operating and free cash flow means PureTech continues to consume cash while advancing its programs. This increases dependence on portfolio monetizations, partner funding or other financing sources and could constrain investment if expected inflows are delayed.
Reduced Future Cobenfy Economics
A lower estimate for remaining Cobenfy proceeds reduces a potentially important source of non-dilutive cash and weakens near-term portfolio monetization expectations. That makes future funding and value creation more dependent on other founded entities and pipeline execution.
PureTech Health News
0VQ0 FAQ
What was PureTech Health’s price range in the past 12 months?
What is PureTech Health’s market cap?
When is PureTech Health’s upcoming earnings report date?
How were PureTech Health’s earnings last quarter?
Is PureTech Health overvalued?
Does PureTech Health pay dividends?
What is PureTech Health’s EPS estimate?
How many shares outstanding does PureTech Health have?
What happened to PureTech Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PureTech Health?
What is the TipRanks Smart Score and how is it calculated?
PureTech Health Stock Smart Score
Company Description
PureTech Health
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert William Henry Lyne
- Employees
- 90
- Website
- www.puretechhealth.com
- Address
- 6 Tide Street, Boston, MA, 02210, US
PureTech Health (0VQ0) Earnings & Revenues
0VQ0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, highlighting successful financing and IPO execution, clinical and regulatory progress, a strong cash runway, lower expected go-forward cash burn and an innovation pipeline ahead of its stated target. The main negatives were the material downgrade in estimated future Cobenfy proceeds, the first-half cash balance decline, higher first-half operating expenses and pending financing requirements for Gallop and Celea.
View all DE:0VQ0 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 12 | 0 | 0 |
